Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.54 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.54 |
| ▸ | TTR | P02766 | 2/20 | 0.54 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.54 |
| ▸ | UGT1A9 | O60656 | 1/20 | 0.54 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.54 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.54 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.54 |
| ▸ | ALB | P02768 | 1/20 | 0.54 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.54 |
| ▸ | UGT1A6 | P19224 | 1/20 | 0.54 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.54 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.54 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.54 |
| ▸ | UGT1A7 | Q9HAW7 | 1/20 | 0.54 |
| ▸ | UGT1A10 | Q9HAW8 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4786132 | 0.85 | TTR (0.60) | PTGS2NR1H4TTRAKR1B10UGT1A9 | |
| SCHEMBL13802509 | 0.85 | CXCL8 (0.57) | PTGS2NR1H4TTRAKR1B10UGT1A9 | |
| SCHEMBL6277797 | 0.84 | GAA (0.60) | PTGS2NR1H4TTRAKR1B10UGT1A9 | |
| SCHEMBL2468368 | 0.82 | AKR1B1 (0.57) | NR1H4SELPSELEHPSEAKR1B1 | |
| SCHEMBL4217521 | 0.81 | SELP (0.49) | NR1H4SELPSELEHPSEAKR1B1 | |
| SCHEMBL7164965 | 0.81 | CYP3A4 (0.59) | NR1H4SELPSELEHPSEAKR1B1 | |
| SCHEMBL10439857 | 0.80 | TOP2A (0.56) | — | |
| SCHEMBL10439650 | 0.78 | RAPGEF4 (0.41) | PTGS2NR1H4TTRAKR1B10UGT1A9 | |
| SCHEMBL10439645 | 0.77 | RAPGEF4 (0.42) | PTGS2NR1H4TTRAKR1B10UGT1A9 | |
| SCHEMBL13370136 | 0.76 | SELP (0.56) | NR1H4SELPSELEHPSEAKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105561311-B | Pharmaceutical composition comprising 3- (3- dimethylamino -1- Ethyl-2-Methyl-propyl)-phenol and NSAID | 格吕伦塔尔有限公司 | 2019-07-16 | — | — | CN | disclosed |
| US-20160361276-A1 | Pharmaceutical Combination | GRUENENTHAL GMBH (DE) | 2016-12-15 | — | — | US | disclosed |
| US-20160045459-A1 | Pharmaceutical Combination | GRUENENTHAL GMBH (DE) | 2016-02-18 | — | — | US | disclosed |
| US-20130267602-A1 | MOISTURE RESISTANT CONTAINER SYSTEMS FOR RAPIDLY BIOAVAILABLE DOSAGE FORMS | APR APPLIED PHARMA RESEARCH, S.A. (CH) | 2013-10-10 | — | — | US | disclosed |
| US-20130267602-A1 | MOISTURE RESISTANT CONTAINER SYSTEMS FOR RAPIDLY BIOAVAILABLE DOSAGE FORMS | APR APPLIED PHARMA RESEARCH, S.A. (CH) | 2013-10-10 | — | — | US | disclosed |
| US-20130190333-A1 | Pharmaceutical Combination | GRUENENTHAL GMBH (DE) | 2013-07-25 | — | — | US | disclosed |
| US-8097267-B2 | Moisture resistant container systems for rapidly bioavailable dosage forms | APR APPLIED PHARMA RESEARCH S.A. (CH) | 2012-01-17 | — | — | US | disclosed |
| US-8097267-B2 | Moisture resistant container systems for rapidly bioavailable dosage forms | APR APPLIED PHARMA RESEARCH S.A. (CH) | 2012-01-17 | — | — | US | disclosed |
| US-20110105443-A1 | SALTS OF MEMANTINE AND COX-INHIBITORS AND THEIR CRYSTAL FORM IN THE TREATMENT OF PAIN | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2011-05-05 | — | — | US | disclosed |
| US-20110105443-A1 | SALTS OF MEMANTINE AND COX-INHIBITORS AND THEIR CRYSTAL FORM IN THE TREATMENT OF PAIN | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2011-05-05 | — | — | US | disclosed |
| US-20110105613-A1 | MOISTURE RESISTANT CONTAINER SYSTEMS FOR RAPIDLY BIOAVAILABLE DOSAGE FORMS | APR APPLIED PHARMA RESARCH SA (CH) | 2011-05-05 | — | — | US | disclosed |
| US-20110105613-A1 | MOISTURE RESISTANT CONTAINER SYSTEMS FOR RAPIDLY BIOAVAILABLE DOSAGE FORMS | APR APPLIED PHARMA RESARCH SA (CH) | 2011-05-05 | — | — | US | disclosed |
| EP-2012763-B1 | PHARMACEUTICAL COMBINATION COMPRISING 3- (3-DIMETHYLAMIN0-1-ETHYL-2-METHYL-PR0PYL) -PHENOL AND AN NSAID | GRUENENTHAL GMBH (DE) | 2011-03-23 | — | — | EP | disclosed |
| WO-2009109401-A1 | SALTS OF MEMANTINE AND COX-INHIBITORS AND THEIR CRYSTALFORM IN THE TREATMENT OF PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-09-11 | — | — | WO | disclosed |
| US-20090099138-A1 | NSAIDs and tapentadol; synergistic pain relief | GRUENENTHAL GMBH (DE) | 2009-04-16 | — | — | US | disclosed |
| EP-2012763-A1 | PHARMACEUTICAL COMBINATION COMPRISING 3- (3-DIMETHYLAMIN0-1-ETHYL-2-METHYL-PR0PYL) -PHENOL AND AN NSAID | Grünenthal GmbH (DE) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007128412-A1 | PHARMACEUTICAL COMBINATION COMPRISING 3- (3-DIMETHYLAMIN0-1-ETHYL-2-METHYL-PR0PYL) -PHENOL AND AN NSAID | Grünenthal GmbH (DE) | 2007-11-15 | — | — | WO | disclosed |
| EP-0377896-A2 | Cyclooxygenase and 5-lipoxygenase inhibiting hydroxamic acid derivatives | CIBA-GEIGY AG (CH) | 1990-07-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105613-A1 | MOISTURE RESISTANT CONTAINER SYSTEMS FOR RAPIDLY BIOAVAILABLE DOSAGE FORMS | CYP2D6, ABCG2, CYP2C19 | PTGS2 17/4885NR1H4 4238/4885TTR 683/4885 |
| US-20160361276-A1 | Pharmaceutical Combination | MC2R, PTGER2, PTGER1 | PTGS2 8/4885NR1H4 954/4885TTR 2743/4885 |
| US-20110105443-A1 | SALTS OF MEMANTINE AND COX-INHIBITORS AND THEIR CRYSTAL FORM IN THE TREATMENT OF PAIN | OPRK1, GRIN2A, HTR2A | PTGS2 29/4885NR1H4 2856/4885TTR 2054/4885 |
| US-20160045459-A1 | Pharmaceutical Combination | MC2R, PTGER2, PTGER1 | PTGS2 8/4885NR1H4 954/4885TTR 2743/4885 |
| US-20130190333-A1 | Pharmaceutical Combination | MC2R, PTGER2, PTGER1 | PTGS2 8/4885NR1H4 954/4885TTR 2743/4885 |
| US-20090099138-A1 | NSAIDs and tapentadol; synergistic pain relief | PTGS1, OPRL1, PTGES3 | PTGS2 5/4885NR1H4 975/4885TTR 1317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.